Baron, F., Suciu, S., Amadori, S., Muus, P., Zwierzina, H., Denzlinger, C., et al. (2012). Value of infliximab (Remicade) in patients with low-risk myelodysplastic syndrome. Final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group. HAEMATOLOGICA, 97, 529-533 [10.3324/haematol.2011.044347].
Value of infliximab (Remicade) in patients with low-risk myelodysplastic syndrome. Final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group
AMADORI, SERGIO;
2012-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
